论文部分内容阅读
作者报道了3例HCL病人,均于脾脏切除后全血细胞减少,在并发输血性肝炎之后2例病人在2个月内有显著血液学改变。所有病人虽然骨髓持续有毛细胞浸润,但在17个月内,外周血相均达完全缓解。1例病人持续缓解达12年。另2例病人虽死于感染性疾病但血相正常。在两组回顾性研究中,患AML病人发生肝炎与其未发生相比,完全缓解持续时间和中数幸存时间有统计学差别。也有报道急性上呼吸道感染之后对特发性血小板减少性紫癜有短暂缓解。据推测肝炎病毒能直接诱导恶性细胞的抑制,增强宿主免疫系统及通过肝炎病毒使抗白血病药物进入白血病细胞的可能。应用α干扰素对大多数HCL病人显著疗效的最新观点提出了病毒性肝炎的有益作用也是激活干扰素系统的结果。输血性肝炎后HCL病人外周血相缓解时
The authors reported 3 HCL patients who had pancytopenia after splenectomy and 2 patients who had significant hematologic changes within 2 months after transfusion hepatitis. Although all patients continued to have hair cells in bone marrow infiltration, but within 17 months, the peripheral blood reached the complete remission. One patient sustained remission for 12 years. The other two patients died of infectious disease but blood normal. In both retrospective studies, there was a statistically significant difference between complete remission duration and median survival in patients with AML who developed hepatitis compared with their non-occurrence. Acute upper respiratory tract infection has also been reported after a transient relief of idiopathic thrombocytopenic purpura. It is speculated that the hepatitis virus can directly induce the inhibition of malignant cells, enhance the host immune system and the possibility that the anti-leukemia drugs enter the leukemia cells through the hepatitis virus. Recent insights into the significant effect of interferon-alpha on most HCL patients suggest that the beneficial effects of viral hepatitis are also the result of activating the interferon system. HCL patients after transfusion of blood to ease the peripheral blood phase